Related Experiment Videos
Antimicrobial effectiveness of povidone-iodine and consequences for new application areas
K Reimer1, T A Wichelhaus, V Schäfer
1Mundipharma GmbH, Limburg, Deutschland. Karen.Reimer@Mundipharma.de
Abstract:
The microbicidal action spectrum of povidone-iodine (PVP-I) is broad - even after short onset times. Unlike local antibiotics and other antiseptic substances, no resistance develops. The high degree of bactericidal efficiency in respect of highly resistant gram-positive pathogenic micro-organisms, such as methicillin-resistant Staphylococcus aureus (MRSA) and enterococcus strains, is particularly significant for hospital hygiene. An in vitro study with 10 genotypically different MRSA isolates showed an optimum bactericidal effect (logarithmic reduction factor value >5) without protein load after just 30 s exposure and even in a dilution of Betaisodona solution (Mundipharma GmbH) of 1%. With protein load (0.2% albumin), the optimum in microbicidal effectiveness shifts to concentrations > or = 10% Betaisodona solution referring to an exposure time of 30 s. Since recent results are now also available on the toxicological safety of PVP-I preparations for the ciliated epithelium of the nasal mucosa and the good tolerability on skin and other mucous membranes is a known factor, a controlled clinical study is currently being carried out to eliminate colonizations of MRSA. Evidence has also recently been produced of the antiviral activity of PVP-I against herpes simplex, adeno- and enteroviruses, as well as its high degree of efficiency against Chlamydia. Hence alongside the classical fields of application, such as the disinfection of the skin and hands, mucosa antisepsis and wound treatment, there are also useful indications for the substance, i.e. rinsing of body cavities and joints and application to the eye.
Insights
Povidone-iodine (PVP-I) demonstrates broad-spectrum microbicidal action without resistance development, proving highly effective against resistant bacteria like MRSA. Its efficacy is maintained even with protein load, supporting its use in diverse clinical applications.
Area of Science:
- Microbiology
- Infectious Diseases
- Antiseptics and Disinfectants
Background:
- Povidone-iodine (PVP-I) possesses a broad microbicidal spectrum with rapid onset.
- Unlike antibiotics, PVP-I does not induce microbial resistance.
- Its effectiveness against highly resistant Gram-positive pathogens like MRSA is crucial for hospital hygiene.
Purpose of the Study:
- To evaluate the in vitro bactericidal efficacy of PVP-I against methicillin-resistant Staphylococcus aureus (MRSA).
- To determine the impact of protein load on PVP-I's microbicidal effectiveness.
- To explore the potential of PVP-I in new clinical applications based on its safety and efficacy profile.
Main Methods:
- In vitro study utilizing 10 genotypically distinct MRSA isolates.
- Exposure time of 30 seconds with varying concentrations of Betaisodona solution.
- Assessment of bactericidal effect with and without protein load (0.2% albumin).
Main Results:
- Optimal bactericidal effect (logarithmic reduction factor >5) achieved with 1% Betaisodona solution within 30s, without protein load.
- With protein load, optimal efficacy shifted to concentrations ≥10% Betaisodona solution at 30s exposure.
- PVP-I demonstrated antiviral activity against herpes simplex, adeno-, and enteroviruses, and high efficacy against Chlamydia.
Conclusions:
- PVP-I exhibits potent and rapid microbicidal activity against MRSA, even under protein-challenging conditions.
- Established safety and tolerability, coupled with broad-spectrum efficacy, support PVP-I's use beyond traditional applications.
- Ongoing clinical studies aim to leverage PVP-I for MRSA colonization elimination, with potential for use in body cavities, joints, and ocular applications.